Dr. Goy Discusses Single-Agent Ibrutinib in MCL

Andre Goy, MD
Published: Monday, Dec 11, 2017



Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

A long-term follow-up of single-agent ibrutinib was presented at the 2017 ASH Annual Meeting. Goy reports that the complete response rate was up to 26%. Additionally, at 3 years, one-quarter of patients still had not progressed.

However, work still needs to be done to determine which patients would benefit best from ibrutinib, Goy adds.
 
SELECTED
LANGUAGE


Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

A long-term follow-up of single-agent ibrutinib was presented at the 2017 ASH Annual Meeting. Goy reports that the complete response rate was up to 26%. Additionally, at 3 years, one-quarter of patients still had not progressed.

However, work still needs to be done to determine which patients would benefit best from ibrutinib, Goy adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x